Asthma management with HFA-BDP (Qvar™)

This report reviews the role of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP; Qvar™, 3M, Loughborough) in the management of asthma, based on pharmacokinetic, efficacy and safety clinical trial data presented at a satellite symposium to the European Respiratory Society in 1998. Qvar provides equivalent efficacy and safety to chlorofluorocarbon-BDP at about half the dose.